Rosen Law Firm Encourages Biomea Fusion, Inc. Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – BMEAGlobeNewsWire • 06/20/24
Starting A Probe Into Claims Against Biomea Fusion Inc The Schall Law Firm Welcomes Investors With Losses To Make ContactAccesswire • 06/19/24
Schall Law Firm Initiates Investigation Into Allegations Against Biomea Fusion Inc And Urges Affected Investors To Get In TouchAccesswire • 06/18/24
The Schall Law Firm Declares Investigation Into Allegations Against Biomea Fusion, Inc. And Urges Investors With Losses To Reach Out To The FirmAccesswire • 06/17/24
Initiating An Investigation Into Allegations Against Biomea Fusion, Inc., The Schall Law Firm Invites Investors With Losses To Reach Out To The FirmAccesswire • 06/12/24
The Schall Law Firm Announces Probe Into Claims Against Biomea Fusion, Inc. And Encourages Investors With Losses To Contact The FirmAccesswire • 06/11/24
This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayBenzinga • 06/11/24
The Schall Law Firm Initiates Investigation into Accusations Against Biomea Fusion, Inc. and Urges Investors Suffering Losses to Liaise with the FirmAccesswire • 06/09/24
The Schall Law Firm Announces Inquiry into Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/08/24
The Schall Law Firm Declares Investigation into Allegations Against Biomea Fusion, Inc. and Invites Investors with Losses to Reach Out to the FirmAccesswire • 06/07/24
Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On HoldInvestors Business Daily • 06/07/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmGlobeNewsWire • 06/07/24
Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish ExpectationsInvestorPlace • 06/06/24
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesGlobeNewsWire • 05/30/24
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/01/24
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219GlobeNewsWire • 04/01/24
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 04/01/24
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionGlobeNewsWire • 03/06/24
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/01/24